Wandall Group

We use gene editing, organotypic tissue models, and sophisticated mass spectrometry to decipher glycan functions. The genetically engineered cells and organotypic tissue model have provided evidence of the importance of glycans in tissue differentiation, cancer, and host-pathogen interactions.

3D vævs/celle model

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Consultant for and founder of GO-therapeutics focusing on development of antibodies for immunotherapy of cancer (http://gotherapeutics.com). 
  • Co-founder of Hemab Therapeutics (https://www.hemab.com), developing therapies for bleeding disorders, and Cymab, developing innovative immunotherapies for the treatment of cancer.
  • Consultant for Ridge Bio (https://ridgebio.com) catalyzing the next generation of precision medicines
  • Established Wandall ApS to control consultant activities. 

 

 

 

The Danish Council for Strategic Research, as represented by the Programme Commission on Strategic Growth Technologies

logo det strategiske forskningsråd

Danish National Research Program "Sapere Aude – Project leader”
sapere aude logo

European Research Council - "ERC Consolidator Grant"
ERC logo

logo for neye

 

 

 

 

 

 

hans wandallGroup Leader

Hans H. Wandall
Professor, MD, PhD
Deputy head of department, Innovation
hhw@sund.ku.dk

(+45) 23 84 01 56 / (+45) 35 33 55 53
CV, publications, etc

Glycomics Program
Copenhagen Center for Glycomics